Sanofi (SNY) Stock Price, News & Analysis

Company Overview

Sanofi is a France-based global healthcare company that researches, develops, manufactures and markets prescription medicines and vaccines. Its operations focus primarily on specialty medicines, immunology, rare diseases, neurology, oncology and treatments for rare blood disorders, as well as established pharmaceutical products.

The company’s portfolio includes Dupixent, an immunology medicine developed with Regeneron; vaccines for influenza, polio, meningitis and other infectious diseases; and treatments for conditions including multiple sclerosis, hemophilia and certain rare diseases. Sanofi also develops medicines for diabetes and other chronic conditions, while its consumer healthcare business operates separately under the Opella brand.

Sanofi traces its history to the French pharmaceutical industry and became the combined Sanofi-Aventis group in 2004 following the merger of Sanofi-Synthélabo and Aventis. Headquartered in Paris, Sanofi serves patients and healthcare providers in markets across Europe, North America, Asia and other regions worldwide. Paul Hudson has served as the company’s chief executive officer since 2019.

Key Stats

• Today's Range: $46.46 to $47.43
• 50-Day Range: $39.12 to $46.02
• 52-Week Range: $39.07 to $52.68
• Volume: 3.74 million shs
• Average Volume: 3.49 million shs
• Market Capitalization: $114.59 billion
• P/E Ratio: 23.40
• Dividend Yield: 3.72%
• Price Target: $49.50
• Consensus Rating: Hold

Sanofi Stock Analysis - MarketRank™

Sanofi scored higher than 72% of companies evaluated by MarketBeat, and ranked 136th out of 893 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 2.6 / 5
• Analyst Rating: Hold

Consensus Rating

Sanofi has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on 1 strong buy rating, 7 buy ratings, 13 hold ratings, and no sell ratings.

Upside/Downside

The consensus price target for Sanofi is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

Sanofi has been the subject of 9 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 3.97%

Earnings Growth

Earnings for Sanofi are expected to grow by 3.97% in the coming year, from $5.04 to $5.24 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Sanofi is 23.46, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.16.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sanofi is 23.46, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 36.36.

Price to Earnings Growth Ratio

Sanofi has a PEG Ratio of 1.25. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

Sanofi has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.48% of the float of Sanofi has been sold short.

Short Interest Ratio / Days to Cover

Sanofi has a short interest ratio ("days to cover") of 3.09, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Sanofi has recently increased by 9.42%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Leadership

Sanofi is a leading dividend payer. It pays a dividend yield of 3.87%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

Sanofi does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sanofi is 87.13%. Payout ratios above 75% are not desirable because they may not be sustainable.

Dividend Sustainability

Based on earnings estimates, Sanofi will have a dividend payout ratio of 33.59% next year. This indicates that Sanofi will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.8 / 5
• News Sentiment: 1.13

News Sentiment

Sanofi has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.42 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 14 news articles for Sanofi this week, compared to 6 articles on an average week.

Search Interest

Only 11 people have searched for SNY on MarketBeat in the last 30 days. This is a decrease of -15% compared to the previous 30 days.

MarketBeat Follows

12 people have added Sanofi to their MarketBeat watchlist in the last 30 days. This is an increase of 500% compared to the previous 30 days.

Company Ownership

• Score: 0.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sanofi insiders have not sold or bought any company stock.

Percentage Held by Insiders

1.00% of the stock of Sanofi is held by insiders.

Percentage Held by Institutions

14.03% of the stock of Sanofi is held by institutions.

Company Calendar

• Last Earnings: 10/30/2026
• Today: 11/04/2026
• Jefferies Global Healthcare Conference: 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SNY
• CIK: 1121404
• Web: www.sanofi.com
• Phone: (315) 377-4000
• Fax: 33-1-53-77-43-03
• Employees: 74,846
• Year Founded: 1994

Price Target and Rating

• Average Price Target for Sanofi: $49.50
• High Price Target: $50.00
• Low Price Target: $49.00
• Potential Upside/Downside: +4.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.43
• Research Coverage: 21 Analysts

Profitability

• EPS (Trailing Twelve Months): $2.02
• Trailing P/E Ratio: 23.40
• Forward P/E Ratio: 9.02
• P/E Growth: 1.25
• Net Income: $8.84 billion
• Net Margins: 8.70%
• Pretax Margin: 12.87%
• Return on Equity: 15.16%
• Return on Assets: 8.48%

Debt

• Debt-to-Equity Ratio: 0.20
• Current Ratio: 1.12
• Quick Ratio: 0.64

Sales & Book Value

• Annual Sales: $49.35 billion
• Price / Sales: 2.32
• Cash Flow: $7.33 per share
• Price / Cash Flow: 6.45
• Book Value: $34.77 per share
• Price / Book: 1.36

Miscellaneous

• Outstanding Shares: 2,424,430,000
• Free Float: 2,400,181,000
• Market Cap: $114.61 billion
• Optionable: Optionable
• Beta: 0.31